secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062003
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q3 net loss $30.4M ($0.20/shr); cash $343.6M; first patient dosed in SEACRAFT-1
--------------------------------------------------------------------------------

- Net loss $30.4M ($0.20/shr) vs $35.5M ($0.29/shr) in Q3 2022; decrease in R&D expenses to $25.2M.
- Cash, equivalents, and marketable securities $343.6M at Sep 30, 2023, down from $435.6M at Dec 31, 2022; runway into H2 2025.
- First patient dosed in SEACRAFT-1 Phase 1b (naporafenib + trametinib) for RAS Q61X solid tumors in Aug 2023.
- Upcoming catalysts: SEACRAFT-1 initial data H2 2024; SEACRAFT-2 Phase 3 start H1 2024; HERKULES-3 expansion data H2 2023-H1 2024.
- THUNDERBBOLT-1 initial Phase 1 monotherapy data in recurrent GBM expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/0000950170-23-062003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/eras-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer